294 related articles for article (PubMed ID: 17718929)
21. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
22. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
23. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
Katzenellenbogen JA
Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
[TBL] [Abstract][Full Text] [Related]
24. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
25. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
[TBL] [Abstract][Full Text] [Related]
26. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
27. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
[TBL] [Abstract][Full Text] [Related]
28. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ
Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512
[TBL] [Abstract][Full Text] [Related]
29. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
[TBL] [Abstract][Full Text] [Related]
30. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
31. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.
Seimbille Y; Rousseau J; Bénard F; Morin C; Ali H; Avvakumov G; Hammond GL; van Lier JE
Steroids; 2002 Aug; 67(9):765-75. PubMed ID: 12123788
[TBL] [Abstract][Full Text] [Related]
32. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
[TBL] [Abstract][Full Text] [Related]
33. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
[TBL] [Abstract][Full Text] [Related]
34. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Liao GJ; Clark AS; Schubert EK; Mankoff DA
J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
[TBL] [Abstract][Full Text] [Related]
35. Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.
Boers J; Schröder CP; Hospers GAP; de Vries EFJ; Glaudemans AWJM
Clin Nucl Med; 2021 Mar; 46(3):e165-e167. PubMed ID: 33181752
[TBL] [Abstract][Full Text] [Related]
36. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.
McGuire AH; Dehdashti F; Siegel BA; Lyss AP; Brodack JW; Mathias CJ; Mintun MA; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1991 Aug; 32(8):1526-31. PubMed ID: 1869973
[TBL] [Abstract][Full Text] [Related]
37. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
[TBL] [Abstract][Full Text] [Related]
38.
Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
[TBL] [Abstract][Full Text] [Related]
39. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
40. A Randomized Feasibility Study of
Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
